Latest News
- FDA Approval/Clearance
Monday, March 11, 2019
FDA Approves Dupixent for Moderate to Severe AD in Adolescents
The FDA has approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged 12 through 17 whose disease is not adequately controlled with topic…
Read the full story
Wednesday, February 27, 2019
FDA Approves Janssen's Tremfya One-Press
The FDA has approved Tremfya® One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis. Tremfya®(guselkumab) from the Janssen Pharmaceutic…
Read the full story
Monday, February 25, 2019
FDA Proposes New Sunscreen Regulations; Experts React
The FDA is updating its position on over-the-counter sunscreens, and according to the new proposal, several popular ingredients require more data. New guidelines do, however, note that zinc oxide…
Read the full storyFriday, February 15, 2019
FDA Proposes Policy for New Competitive Generic Therapies Pathway
The FDA has issued a new policy it says is intended to improve access and increase competition for drugs that lack generic competition. The new pathway for Competitive Generic Therapies (CGTs…
Read the full story
Tuesday, February 12, 2019
Lutronic Genius RF Microneedling Platform Cleared by FDA
Lutronic has received FDA clearance of the Lutronic Genius™ platform for radiofrequency microneedling. The company says the device transmits energy more precisely into the skin. …
Read the full story
Saturday, February 02, 2019
Jeuveau from Evolus Now FDA Cleared for Aesthetic Injection
The FDA has approved Jeuveau™ (prabotulinumtoxinA-xvfs), the lead product from Evolus, Inc., for the temporary improvement in the appearance of moderate to severe glabellar lines associated with…
Read the full storyTuesday, November 06, 2018
US FDA Grants Dupixent Priority Review for Moderate-to-Severe AD in Adolescents
The US Food and Drug Administration (FDA) has granted Priority Review for Dupixent (dupilumab) as a potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis (AD). …
Read the full story
Monday, November 05, 2018
FDA Approves Galderma’s Restylane Lyft for Midface Injection Via Cannula
The U.S. Food and Drug Administration (FDA) has approved the use of Galderma’s Restylane Lyft with a small, blunt-tip cannula for cheek augmentation and the correction of age-related midface con…
Read the full storyThursday, October 11, 2018
Study: Positive Safety and Tolerability Results for Ortho Dermatologics' Altreno for Acne
Ortho Dermatologics shared results of two identical Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel group studies examining the efficacy and safety of Altreno (tretinoin) …
Read the full storyMonday, October 08, 2018
Ortho Dermatologics Receives Tentative FDA Approval for Bryhali for Plaque Psoriasis
The FDA has provided tentative approval of the New Drug Application for Bryhali (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients. Bryhali Lotion …
Read the full story
Wednesday, October 03, 2018
FDA Approves Paratek's Nuzyra
The FDA has approved Paratek Pharmaceuticals, Inc's Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infection…
Read the full storyWednesday, October 03, 2018
Dermira’s Qbrexa Cloth Now Available for Primary Axillary Hyperhidrosis
Dermira, Inc.'s Qbrexa (glycopyrronium) cloth is now available for prescribing to treat primary axillary hyperhidrosis. The new therapy is available in retail and community pharmacies nationwide. …
Read the full story
Tuesday, October 02, 2018
Seysara: Oral Antibiotic is First Approved for Dermatology in 40 Years
Seysara (sarecycline), a new, first in class tetracycline-derived oral antibiotic, is now approved for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients…
Read the full story
Friday, September 28, 2018
FDA Approves Regeneron's Libtayo, First Treatment for Metastatic or Locally Advanced SCC
Libtayo (cemiplimab-rwlc) injection (Regeneron Pharmaceuticals, Inc.) is now FDA-approved for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma…
Read the full story
Friday, September 21, 2018
FDA Green Lights First Spray-on-Skin Product for Burns
The US Food and Drug Administration granted premarket approval to Avita Medical’s Recell, a spray-on-skin that treats second- and third-degree burns in patients aged older than 18 years. The …
Read the full story
